Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation.
HCV-related disease is the most common indication for liver transplantation (LT). HCV recurrence, which is almost universal, has a significant impact on patient and graft survival after LT and still represents a great unsolved issue for the liver transplant community. Several treatment strategies have been proposed. Since antiviral therapy has limited efficacy and can be administrated only in selected transplant recipients and additionally that immunosuppressive drugs have a negative impact on HCV re-infection, the achievement of an immunosuppression-free state after LT could play a central role in the avoidance of rapid HCV recurrence.
UOC Trapianti d'Organo, Tor Vergata University, Rome, Italy. tomanzia@libero.it
Tommaso Maria
TM
Manzia
Roberta
R
Angelico
Luca
L
Toti
Quirino
Q
Lai
Paolo
P
Ciano
Mario
M
Angelico
Giuseppe
G
Tisone
D005260:Female; D016174:Hepacivirus; D006526:Hepatitis C / Q000276:immunology / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D055502:Secondary Prevention
D007166:Immunosuppressive Agents